目的 探討甘露特鈉聯(lián)合加蘭他敏治療血管性癡呆的臨床療效。方法 選取2021年7月—2023年6月上海市寶山區(qū)羅店醫(yī)院收治的血管性癡呆患者100例，隨機(jī)分為對(duì)照組（50例）和治療組（50例）。對(duì)照組患者iv氫溴酸加蘭他敏注射液，2 mg/次，2次/d。在對(duì)照組的基礎(chǔ)上，治療組口服甘露特鈉膠囊，3粒/次，2次/d；兩組用藥28 d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀緩解時(shí)間，日常生活功能量表（ADL）和簡易精神狀態(tài)量表（MMSE）評(píng)分，血清炎性因子超氧化物歧化酶（SOD）、脂蛋白相關(guān)磷脂酶A₂（Lp-PLA₂）、白細(xì)胞介素1β（IL-1β）和腦源性神經(jīng)營養(yǎng)因子（BDNF）水平。結(jié)果 治療后，治療組總有效率88.00%，明顯高于對(duì)照組（70.00%，P＜0.05）。治療后，治療組癥狀好轉(zhuǎn)時(shí)間均明顯早于對(duì)照組（P＜0.05）。治療后，兩組患者ADL評(píng)分明顯降低，而MMSE評(píng)分明顯升高（P＜0.05），且治療組ADL和MMSE評(píng)分明顯好于對(duì)照組（P＜0.05）。治療后，兩組患者血清炎性因子IL-1β和Lp-PLA₂水平明顯降低，而SOD和BDNF水平明顯升高（P＜0.05），且治療組血清炎性因子水平明顯好于對(duì)照組（P＜0.05）。結(jié)論 甘露特鈉聯(lián)合加蘭他敏治療血管性癡呆可顯著緩解臨床癥狀，并能有效降低機(jī)體炎性反應(yīng)狀態(tài)，日常生活能力有效增強(qiáng)。

Objective To explore the clinical effect of sodium oligomannate combined with galantamine in treatment of vascular dementia. Methods Patients (100 cases) with vascular dementia in Shanghai Baoshan Luodian Hospital from July 2021 to June 2023 were randomly divided into control (50 cases) and treatment (50 cases) group. Patients in the control group were iv administered with Galantamine Hydrobromide Injection, 2 mg/time, twice daily. Patients in the treatment group were po administered with Sodium Oligomannate Capsules on the basis of the control group, 3 grains/time, twice daily. Patients in two groups were treated for 28 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, the scores of ADL and MMSE, the levels of serum IL-1β, Lp-PLA₂, SOD and BDNF in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 88.00%, which was significantly higher than that of the control group (70.005%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the ADL score in two groups was significantly decreased, while the MMSE score was significantly increased (P < 0.05), and the ADL and MMSE scores in the treatment group were significantly better than those of the control group (P < 0.05). After treatment, the levels of serum inflammatory factors IL-1β and Lp-PLA₂ were significantly decreased, while the levels of SOD and BDNF were significantly increased in two groups (P < 0.05), and the level of serum inflammatory factors in the treatment group were significantly better than that in the control group (P < 0.05). Conclusion The synergistic treatment of galantamine and sodium oligomannate can significantly alleviate clinical symptoms, which can effectively reduce the inflammatory response state, effectively enhance daily living ability.

R971